| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | World | | US | | Emerging Markets | | Europe | | Established RoW | For the quarter ended 30 June | | | | Change | | | | Change | | | | Change | | | | Change | | | | Change | | | $m | | Act % | | CER % | | $m | | Act % | | $m | | Act % | | CER % | | $m | | Act % | | CER % | | $m | | Act % | | CER % | Tagrisso | | 1,941 | | 7 | | 6 | | 845 | | 11 | | 512 | | 5 | | 1 | | 383 | | 9 | | 4 | | 201 | | (3) | | 2 | Imfinzi | | 1,854 | | 27 | | 27 | | 1,054 | | 25 | | 211 | | 39 | | 36 | | 398 | | 39 | | 34 | | 191 | | 10 | | 17 | Calquence | | 1,022 | | 17 | | 16 | | 687 | | 18 | | 67 | | 36 | | 30 | | 225 | | 13 | | 9 | | 43 | | 3 | | 3 | Lynparza | | 829 | | (1) | | (3) | | 351 | | (7) | | 170 | | 4 | | (2) | | 240 | | 5 | | 1 | | 68 | | (2) | | 3 | Enhertu | | 338 | | 47 | | 44 | | - | | - | | 223 | | 43 | | 41 | | 68 | | 34 | | 28 | | 47 | | n/m | | 98 | Zoladex | | 304 | | 7 | | 2 | | 5 | | 10 | | 239 | | 9 | | 4 | | 42 | | 10 | | 5 | | 18 | | (23) | | (24) | Truqap | | 233 | | 37 | | 37 | | 168 | | 18 | | 17 | | n/m | | n/m | | 34 | | n/m | | n/m | | 14 | | 77 | | 85 | Imjudo | | 83 | | (7) | | (7) | | 51 | | (11) | | 7 | | (3) | | (3) | | 14 | | 25 | | 20 | | 11 | | (21) | | (16) | Datroway | | 4 | | n/m | | n/m | | - | | - | | 4 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Etcamah | | 3 | | n/m | | n/m | | - | | - | | 3 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Other Oncology | | 102 | | (4) | | (5) | | 2 | | 58 | | 69 | | (2) | | (5) | | 4 | | (15) | | (28) | | 27 | | (11) | | (3) | Oncology | | 6,713 | | 15 | | 13 | | 3,163 | | 14 | | 1,522 | | 16 | | 12 | | 1,408 | | 19 | | 14 | | 620 | | 5 | | 10 | Farxiga | | 1,804 | | (16) | | (19) | | 219 | | (48) | | 694 | | (19) | | (24) | | 808 | | 6 | | 1 | | 83 | | (22) | | (19) | Crestor | | 331 | | 4 | | 1 | | 10 | | (18) | | 299 | | 9 | | 5 | | - | | - | | - | | 22 | | (31) | | (27) | Brilinta | | 80 | | (62) | | (63) | | 2 | | (98) | | 66 | | 5 | | 3 | | 11 | | (79) | | (80) | | 1 | | (31) | | (17) | Lokelma | | 221 | | 26 | | 26 | | 85 | | 13 | | 48 | | 47 | | 40 | | 47 | | 54 | | 46 | | 41 | | 12 | | 22 | Seloken | | 157 | | 6 | | 2 | | - | | - | | 153 | | 6 | | 2 | | 3 | | (1) | | (3) | | 1 | | 12 | | 4 | roxadustat | | 14 | | (81) | | (82) | | - | | - | | 14 | | (81) | | (82) | | - | | - | | - | | - | | - | | - | Wainua | | 70 | | 58 | | 58 | | 64 | | 50 | | 1 | | n/m | | n/m | | 4 | | n/m | | n/m | | 1 | | n/m | | n/m | Baxfendy | | 3 | | n/m | | n/m | | 2 | | n/m | | 1 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Other CVRM | | 91 | | (34) | | (35) | | (7) | | n/m | | 70 | | 5 | | 2 | | 14 | | (64) | | (64) | | 14 | | (20) | | (14) | CVRM | | 2,771 | | (15) | | (18) | | 375 | | (44) | | 1,346 | | (11) | | (15) | | 887 | | - | | (4) | | 163 | | (16) | | (12) | Symbicort | | 671 | | (6) | | (8) | | 254 | | (20) | | 191 | | 14 | | 10 | | 145 | | 6 | | 2 | | 81 | | (12) | | (14) | Fasenra | | 570 | | 14 | | 13 | | 338 | | 10 | | 46 | | 81 | | 75 | | 129 | | 3 | | (1) | | 57 | | 29 | | 34 | Breztri | | 346 | | 22 | | 20 | | 161 | | 9 | | 93 | | 43 | | 35 | | 62 | | 36 | | 31 | | 30 | | 23 | | 26 | Tezspire | | 172 | | 54 | | 51 | | - | | - | | 24 | | n/m | | n/m | | 107 | | 49 | | 42 | | 41 | | 33 | | 41 | Saphnelo | | 209 | | 25 | | 24 | | 175 | | 21 | | 7 | | 68 | | 64 | | 19 | | 58 | | 51 | | 8 | | 31 | | 38 | Pulmicort | | 120 | | 13 | | 9 | | 2 | | 11 | | 97 | | 20 | | 15 | | 14 | | (5) | | (9) | | 7 | | (17) | | (17) | Airsupra | | 50 | | 19 | | 18 | | 45 | | 9 | | 5 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Other R&I | | 69 | | 13 | | 9 | | 7 | | (55) | | 27 | | (1) | | (8) | | 33 | | n/m | | n/m | | 2 | | 6 | | 5 | R&I | | 2,207 | | 11 | | 9 | | 982 | | - | | 490 | | 29 | | 24 | | 509 | | 21 | | 16 | | 226 | | 9 | | 11 | Beyfortus | | 47 | | (52) | | (52) | | 38 | | (49) | | - | | - | | - | | 8 | | (66) | | (67) | | 1 | | 34 | | 58 | FluMist | | 18 | | 79 | | 78 | | (2) | | n/m | | 1 | | n/m | | n/m | | - | | - | | - | | 19 | | 90 | | 82 | Other ID | | 34 | | (31) | | (34) | | (1) | | 73 | | 30 | | (20) | | (26) | | 1 | | 78 | | 69 | | 4 | | (68) | | (66) | ID* | | 99 | | (37) | | (38) | | 35 | | (52) | | 31 | | (18) | | (24) | | 9 | | (62) | | (64) | | 24 | | 7 | | 6 | Ultomiris | | 1,314 | | 12 | | 12 | | 719 | | 8 | | 87 | | 42 | | 41 | | 307 | | 14 | | 9 | | 201 | | 12 | | 19 | Soliris | | 389 | | (27) | | (28) | | 199 | | (29) | | 135 | | (15) | | (19) | | 28 | | (50) | | (50) | | 27 | | (21) | | (22) | Strensiq | | 536 | | 36 | | 36 | | 452 | | 42 | | 16 | | 2 | | 2 | | 37 | | 20 | | 14 | | 31 | | 7 | | 15 | Koselugo | | 177 | | 29 | | 27 | | 52 | | - | | 54 | | 51 | | 45 | | 50 | | 34 | | 27 | | 21 | | 78 | | 90 | Other Rare Disease | | 74 | | 36 | | 33 | | 30 | | 8 | | 13 | | n/m | | n/m | | 20 | | 11 | | 5 | | 11 | | n/m | | n/m | Rare Disease | | 2,490 | | 9 | | 8 | | 1,452 | | 8 | | 305 | | 10 | | 6 | | 442 | | 7 | | 3 | | 291 | | 13 | | 20 | Other Medicines | | 230 | | (4) | | (6) | | 19 | | (9) | | 166 | | (10) | | (13) | | 25 | | 52 | | 51 | | 20 | | 12 | | 14 | Total Medicines | | 14,510 | | 5 | | 4 | | 6,026 | | 3 | | 3,860 | | 4 | | - | | 3,280 | | 11 | | 7 | | 1,344 | | 4 | | 9 |
The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. * ID: Infectious Disease
|